Literature DB >> 9675506

Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to subjective response to neuroleptics; attitudes to medication and insight.

J Garavan1, S Browne, M Gervin, A Lane, C Larkin, E O'Callaghan.   

Abstract

The relationship between compliance, subjective response to neuroleptics, attitudes to medication, and insight was assessed in a selected group of individuals with schizophrenia who were attending a catchment area outpatient psychiatric service. Regular compliers with medication reported a significantly better subjective response to neuroleptics and were more frequently prescribed depot medication compared with individuals who were irregularly compliant. There was no difference between regular and irregular compliers in terms of attitudes to medication or level of insight. There was a significant correlation between the measures of insight obtained using a self-report questionnaire (the Insight Scale [IS]) and a semistructured interview (the Scale for Assessment of Insight [SAI]).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9675506     DOI: 10.1016/s0010-440x(98)90063-3

Source DB:  PubMed          Journal:  Compr Psychiatry        ISSN: 0010-440X            Impact factor:   3.735


  16 in total

1.  Social interaction and drug attitude effectiveness in patients with schizophrenia.

Authors:  Jui-Kang Tsai; Wen-Kuo Lin; For-Wey Lung
Journal:  Psychiatr Q       Date:  2011-12

2.  Determinants of changes in perceived quality of life in the course of schizophrenia.

Authors:  Michael Ritsner; Anatoly Gibel; Yael Ratner
Journal:  Qual Life Res       Date:  2006-04       Impact factor: 4.147

Review 3.  Correlates and long-term consequences of poor insight in patients with schizophrenia. A systematic review.

Authors:  Tania M Lincoln; Eva Lüllmann; Winfried Rief
Journal:  Schizophr Bull       Date:  2007-02-08       Impact factor: 9.306

Review 4.  Tactics and technologies to manage nonadherence in patients with schizophrenia.

Authors:  William M Glazer; Mathew J Byerly
Journal:  Curr Psychiatry Rep       Date:  2008-08       Impact factor: 5.285

Review 5.  First-episode schizophrenia: a focus on pharmacological treatment and safety considerations.

Authors:  Deanna L Kelly; Robert R Conley; William T Carpenter
Journal:  Drugs       Date:  2005       Impact factor: 9.546

6.  Insight, quality of life, and functional capacity in middle-aged and older adults with schizophrenia.

Authors:  Ashley S Roseman; John Kasckow; Ian Fellows; Katerine Osatuke; Thomas L Patterson; Somaia Mohamed; Sidney Zisook
Journal:  Int J Geriatr Psychiatry       Date:  2008-07       Impact factor: 3.485

7.  Compliance therapy: a randomised controlled trial in schizophrenia.

Authors:  Colin O'Donnell; Gary Donohoe; Louise Sharkey; Nicholas Owens; Maria Migone; Raewynn Harries; Anthony Kinsella; Conall Larkin; Eadbhard O'Callaghan
Journal:  BMJ       Date:  2003-10-11

8.  Cognitive deficits in psychiatric disorders: Current status.

Authors:  J K Trivedi
Journal:  Indian J Psychiatry       Date:  2006-01       Impact factor: 1.759

9.  A prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia.

Authors:  Rachel Miller; Geoffrey Ream; Joanne McCormack; Handan Gunduz-Bruce; Serge Sevy; Delbert Robinson
Journal:  Schizophr Res       Date:  2009-05-28       Impact factor: 4.939

10.  Attitudes toward medication and the clinical variables in schizophrenia: Structural equation models.

Authors:  Alessandro Rossi; Roberta Pacifico; Paolo Stratta
Journal:  Patient Prefer Adherence       Date:  2009-11-03       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.